thesis-toulmin
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
2
Q37450554-03197C0B-27CA-4D71-9D24-88237060A56D
Q37450554-03197C0B-27CA-4D71-9D24-88237060A56D
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37450554-03197C0B-27CA-4D71-9D24-88237060A56D
Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: a report from the Children's Oncology Group (ANBL0621).
P2860
Q37450554-03197C0B-27CA-4D71-9D24-88237060A56D
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37450554-03197C0B-27CA-4D71-9D24-88237060A56D
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
d4109d750b99e40088c50ab6d10fb792b58e0afe
P2860
A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors.